ArticleJournal of pain research2026
Ultrasound-Guided Cervical Vagus Nerve Block for Postoperative Opioid Consumption After Thoracoscopic Lung Surgery: Study Protocol for a Randomized Controlled Trial.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Effective analgesia after video-assisted thoracoscopic surgery (VATS) remains challenging, as conventional regional techniques mainly target somatic pain but insufficiently address visceral nociception transmitted via the vagus nerve. Cervical vagus nerve block (CVNB) is a novel ultrasound-guided regional technique that may attenuate vagally mediated visceral pain. However, high-quality randomized evidence on its analgesic efficacy and safety after VATS is lacking. This trial aims to evaluate whether adding CVNB to standard thoracic paravertebral block (TPVB) reduces postoperative opioid consumption in patients undergoing VATS lung resection. Methods and Analysis: This randomized, double-blind, placebo-controlled trial will enroll adult patients scheduled for elective VATS. Participants will be randomly assigned (1:1) to receive either 5 mL of 0.375% ropivacaine for CVNB (intervention group) or an equal volume of normal saline (placebo group), in addition to standardized TPVB. The primary outcome is cumulative opioid consumption within 24 hours postoperatively, expressed as intravenous morphine milligram equivalents (MME). Secondary outcomes include postoperative pain scores, time to first rescue analgesia, incidence of nausea and vomiting, quality of recovery, and sleep quality after surgery. A total of 110 patients are required to detect a clinically meaningful reduction in opioid consumption. Ethics and Dissemination: The study was approved by the Ethics Committee of Beijing Chaoyang Hospital (2025-ke-16) and has been registered on www.chictr.org.cn. Results will be disseminated through peer-reviewed journals and academic conferences. This study will be conducted in accordance with the principles of the Declaration of Helsinki. Trial Registration Number: Chinese Clinical Trial Registry: ChiCTR2500096880.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.